Comparative Pharmacology
Head-to-head clinical analysis: NEOMYCIN SULFATE TRIAMCINOLONE ACETONIDE versus STERI STAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEOMYCIN SULFATE TRIAMCINOLONE ACETONIDE versus STERI STAT.
NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE vs STERI-STAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Neomycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis. Triamcinolone acetonide is a corticosteroid that induces phospholipase A2 inhibitory proteins, thereby decreasing prostaglandin and leukotriene synthesis, and exerts anti-inflammatory, antipruritic, and vasoconstrictive effects.
Binds to the 50S ribosomal subunit of bacteria, inhibiting protein synthesis by blocking peptide bond formation and translocation.
Topical: Apply thin film to affected area 2-4 times daily. Otic: Instill 3-4 drops into ear canal 2-3 times daily. Not for systemic use.
Adults: 1 gram intravenously every 8 hours infused over 60 minutes.
None Documented
None Documented
Neomycin: 2-3 hours (normal renal function); in renal impairment, prolonged up to 12-24 hours. Triamcinolone acetonide: 2-5 hours (terminal).
Terminal elimination half-life is 8-12 hours in adults with normal renal function; prolonged to 18-24 hours in moderate renal impairment (CrCl 30-50 mL/min).
Neomycin: >90% orally administered excreted unchanged in feces; absorbed fraction (3-6%) excreted renally with 50% within 24 hours. Triamcinolone acetonide: primarily hepatic metabolism, renal excretion of metabolites (~40% as 11-keto derivatives), fecal excretion ~20%.
Renal excretion of unchanged drug accounts for approximately 95% of elimination; biliary/fecal elimination is minimal (<5%).
Category D/X
Category C
Corticosteroid
Corticosteroid